Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology
NCT04826458 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124
Last updated 2025-12-03
Summary
This is a multicenter, interventional, non-pharmacological study on a app for oral anticancer therapy management.
A total of 124 patients will be considered.
Patients will be randomized 1:1 to one of the following interventions:
A. electronic diary B. paper diary The primary aim of the study is to assess the effectiveness of the electronic diary in improving adherence to oral therapy treatment compared to the paper diary, in patients with solid and haematological tumors.
Conditions
- Cancer
- Solid Tumor
- Hematologic Malignancy
- Oral Drug Administration
Interventions
- DEVICE
-
TreC-Onco
At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the "alarm" function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission.
- OTHER
-
Paper diary
Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
Sponsors & Collaborators
-
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
lead OTHER
Principal Investigators
-
Alessandro Passardi, MD · IRCCS IRST
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-04
- Primary Completion
- 2025-11-11
- Completion
- 2025-11-11
Countries
- Italy
Study Locations
More Related Trials
-
INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS
NCT03955848 ·Status: UNKNOWN ·Phase: NA
-
Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia
NCT04885127 ·Status: COMPLETED ·Phase: NA
-
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00005823 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT05554406 ·Status: RECRUITING ·Phase: PHASE2
-
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
NCT02320656 ·Status: COMPLETED ·Phase: NA
-
Treatment of Adult ALL With an MRD-directed Programme.
NCT00358072 ·Status: COMPLETED ·Phase: PHASE2
-
A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT04745676 ·Status: COMPLETED ·Phase: NA
-
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
NCT01540812 ·Status: COMPLETED
-
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
NCT00002531 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
NCT03823352 ·Status: COMPLETED ·Phase: PHASE2
-
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
NCT04454580 ·Status: UNKNOWN
-
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
NCT00002766 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
NCT00002719 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839 ·Status: RECRUITING ·Phase: PHASE1
-
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00002865 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Differentiation Induction in Acute Myelogenous Leukemia
NCT00175812 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
NCT02665143 ·Status: COMPLETED ·Phase: PHASE2
-
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
NCT02688140 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
NCT00004128 ·Status: UNKNOWN ·Phase: PHASE3
-
Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia
NCT03789981 ·Status: ACTIVE_NOT_RECRUITING
-
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia
NCT01260714 ·Status: TERMINATED ·Phase: PHASE1
-
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
NCT01145846 ·Status: UNKNOWN ·Phase: PHASE3